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Fifty-one children with Mediterranean spotted fever (MSF)
were randomized to receive either clarithromycin, 15 mg/kg/
day orally in 2 divided doses, or chloramphenicol, 50 mg/
kg/day orally in 4 divided doses, for 7 days. Mean time to
defervescence was 36.7 h in the clarithromycin group and
47.1 h in the chloramphenicol group ( ). Clarithro-Pp .047
mycin could be an acceptable therapeutic alternative to
chloramphenicol and to tetracyclines for children aged !8
years with MSF.
Mediterranean spotted fever (MSF) is caused by Rickettsia con-
orii and transmitted by the dog tick Rhipicephalus sanguineus.
It is an acute infectious disease typically characterized by fever,
skin rash, and a black scar at the site of a tick bite (“tache
noire”). Three hundred cases are reported every year (mainly
from June through September) on the Italian island of Sicily
[1]. In North America MSF is the most frequently imported
variety of rickettsiosis [2].
R. conorii is an obligate intracellular bacterium, and the main
feature of MSF is a generalized vasculitis in which R. conorii
are localized within the endothelial cells [3]. Effective intra-
cellular antimicrobial concentrations are considered the sine
qua non of a successful treatment for this disease. The ma-
crolides chloramphenicol and doxycycline penetrate eukaryotic
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membranes and concentrate within the cytoplasm of phagocytic
cells.
Standard treatment for MSF is the oral or parenteral ad-
ministration of tetracyclines or chloramphenicol. However,
both of these drugs have significant adverse effects, especially
in children. Tetracyclines can cause staining of the teeth and
bone toxicity; chloramphenicol can cause gray-baby syndrome,
aplastic anemia, and acute hemolytic anemia in patients with
the Mediterranean form of glucose-6-phosphate dehydrogenase
(G6PD) deficiency. During the past 10 years, we have regarded
chloramphenicol as “the lesser of two evils” and have used this
antibiotic as the drug of choice for treatment of MSF in children
[1].
The macrolides clarithromycin, azithromycin, roxithromy-
cin, and josamycin, which are often used to treat infections in
children, lack such adverse effects and seem to be effective in
vitro against R. conorii [4–6]. Recently, 14 hydroxy-clarithro-
mycin, the primary metabolite of clarithromycin, has been
demonstrated to attain serum concentrations 3 times greater
than its MIC [4, 5]. Given this background information, we
thought it appropriate to undertake a randomized clinical trial
comparing the efficacy and safety of clarithromycin versus chlo-
ramphenicol as treatment for MSF in children.
Patients and methods. All patients with clinically sus-
pected MSF who were admitted to the “G. Di Cristina” chil-
dren’s hospital in Palermo, Italy, from June through September
1998 were evaluated for possible inclusion in the study. At
admission, a complete physical examination and laboratory
tests were performed. Indirect immunofluorescence assay for
R. conorii was performed using a commercial kit (Rickettsia
Conofi-Spot IF; bioMerieux).
Exclusion criteria were as follows: age 114 years, lack of
parental informed consent, history of allergy to the drugs being
studied, severe disease (e.g., neurological signs, hemorrhagic
manifestations, or sepsis), renal or liver insufficiency, immu-
nodeficiency, G6PD deficiency, or previous treatment with anti-
biotic agents potentially active against Rickettsia species in the
7 days before hospitalization.
After informed consent was obtained, children with clinically
suspected MSF and without exclusion criteria were randomly
assigned to receive 7 days of treatment with either clarithro-
mycin (Abbott), 15 mg/kg/day orally in 2 divided doses, or
chloramphenicol (Pharmacia), 50 mg/kg/day orally in 4 divided
doses. Patients were randomized to 1 of the 2 treatment groups
by means of a list of computer-generated random numbers.
The final study population was the group of enrolled children
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Table 1. Baseline characteristics of the 51 patients with Mediterranean
spotted fever, according to drug treatment group.
Characteristic
Drug treatment group
P
Chloramphenicol
(n p 26)
Clarithromycin
(n p 25)
Male sex 14 16 NS
Age, yearsa 5.2  2.6 7.1  3.6 .035
Fever 26 25 NS
Duration of fever before
treatment, mean days 3  1.3 3.3  1.7 NS
Exanthema 26 25 NS
Tache noire 26 25 NS
ESR, mm/h 22.5  9.2 27.9  11.7 NS
AST level, IU/L 57.3  25 40.2 18.8 NS
WBC count, cells  103/mL 6077  2464 6954  2745 NS
Platelet count, cells  103/mL 214  57.4 185  56.7 NS
NOTE. Data are no. of patients or of the specified unit. ESR, erythrocytemeanSD
sedimentation rate; AST, aspartate aminotransferase; tache noire, a black scar at the
site of a tick bite; NS, not significant.
a There were no significant differences between the 2 groups with respect to char-
acteristics at presentation (by Student t test or x2 test), except age.
who had a confirmed diagnosis of MSF. Diagnosis was consid-
ered confirmed if the patient had a score 125 for the MSF
diagnostic test described by Raoult et al. [7].
Clinical response to antibiotic treatment was evaluated on
the basis of the pattern of body temperature and the improve-
ment of the clinical signs and symptoms of the disease. The
end point was defined as the first achievement of persistent
defervescence, which was defined as an axillary temperature
37C for at least 3 consecutive days. Nurses and parents were
instructed to give paracetamol, 10 mg/kg, every time a patient’s
temperature was 138.5C, but not 14 times per day. If the
patient was discharged before day 7 of the hospitalization, the
parents were told to check the child’s temperature at least twice
daily, to call us if fever or other problems reappeared, and to
continue to administer the assigned treatment to complete the
7-day regimen.
The data were analyzed using StatSoft software (Statistica).
Contingency data were analyzed by 2-tailed x2 test or Fisher’s
exact test, and continuous data were analyzed by use of Student
t test. The Pearson correlation coefficient was computed to
verify the existence of correlations between variables. A 2-sided
P value !.05 was considered significant for all analyses.
Results. Seventy-five patients with suspected MSF were
admitted to the hospital during the study period. Seven patients
who had received drugs that are potentially active against Rick-
ettsia species during the 7 days preceding the study were ex-
cluded from the study. Sixty-eight patients were randomized
to receive the study drugs. Fifty-one of these 68 patients had
an MFS diagnostic score 125 and comprised the final study
population; 26 had been assigned to receive chloramphenicol
and 25 to receive clarithromycin. The baseline characteristics
of these patients are summarized in table 1; the patients in the
2 treatment groups were similar with respect to major demo-
graphic variables and characteristics of MSF at study enrollment
except that the mean age of the clarithromycin group was 2
years greater than that of the chloramphenicol group (Pp
; x2 test)..035
All patients received the assigned therapy for 7 days and had
recovered by the end of therapy. Defervescence was achieved
at a mean of h (range, 3–84 h) induration SD 36.7 18.1
the clarithromycin group and h (range, 12–96 h)47.1 21.9
in the chloramphenicol group; these differences were statisti-
cally significant ( ; ). There was no significanttp 2.14 Pp .047
difference between the 2 groups with respect to the use of
paracetamol (used by all patients), nonsteroidal anti-inflam-
matory drugs (used by none of the patients), or corticosteroids
(used by 3 patients in the clarithromycin group and by 2 in
the chloramphenicol group; for all 3 comparisons). TheP 1 .20
median duration of exanthema after the beginning of therapy
was 3 days (range, 1–5 days) for both groups. To exclude the
possibility that the more rapid defervescence in the clarithro-
mycin group was due to the greater mean age of these patients,
a Pearson correlation coefficient was computed. A correlation
between these 2 variables was excluded ( ; ).rp .04 Pp .7
No relapses were observed during 30 days of follow-up. In
all patients, a 4-fold increase in the antibody titer to R. conorii
was observed on day 30. Clarithromycin and chloramphenicol
were equally well tolerated and no major side effects were ob-
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served; vomiting was reported for 2 patients treated with clar-
ithromycin and for 1 treated with chloramphenicol. None of
the patients required discontinuation of the drugs.
Discussion. Until now there has not been a gold-standard
therapy for children with rickettsial diseases. The few studies
that have evaluated the in vitro activity of macrolides against
R. conorii [4–6] suggest that clarithromycin therapy may be of
interest because its pharmacological and pharmacokinetic
properties are possibly superior to those of other macrolides
[5]. Moreover, the combination of clarithromycin and its 14-
hydroxy metabolite produce MICs and postantibiotic effects
that are greater than those associated with use of clarithromycin
alone [4].
Extracellular antimicrobial concentrations may not be ade-
quate to eliminate intracellular pathogens, especially for some
of the new macrolides that exhibit a large volume of distribution
into cells and tissue [4]. Until future studies determine the true
intracellular (endothelial) MIC and maximum concentration
for macrolide treatment of infection with Rickettsia species, we
must continue to rely on determination plasma concentrations
and assume that adequate phagocytic membrane penetration
occurs. Because in vitro antimicrobial data cannot demonstrate
a direct clinical correlation to the selection and use of anti-
microbial pharmacotherapy, animal and human clinical trials
are needed to determine the specific role that these agents may
play in the treatment of these infections [5].
To the best of our knowledge, no other studies have been
conducted on the use of clarithromycin therapy to treat MSF.
Three randomized clinical trials have been performed to eval-
uate macrolides as treatment for MSF. The first of these trials
compared 10 days of treatment with tetracycline hydrochloride
(10 mg/kg q.i.d.) with 10 days of treatment with erythromycin
stearate (12.5 mg/kg q.i.d.) in 81 children [8]. The second study
compared 5 days of treatment with doxycycline (5 mg/kg once
daily) with 3 days of treatment with azithromycin (10 mg/kg
once daily) in 30 children [9]. The third study compared 1 day
of treatment with doxycycline (2.5 mg/kg b.i.d.) with 5 days
of treatment with josamycin (25 mg/kg b.i.d.) in 27 adults and
32 children [10]. The first trial showed that the patients treated
with tetracycline hydrochloride had more rapid disappearance
of fever and clinical symptoms than did patients treated with
erythromycin [8]. However, the in vitro activity of erythro-
mycin against R. conorii is not as potent as that of newer ma-
crolides, such as clarithromycin. The second trial showed that
azithromycin and doxycycline have equal efficacy [9]. In the
third trial, no statistically significant differences were observed
between the doxycycline group and the josamycin group [10].
Both of the latter 2 studies enrolled small numbers of children;
however, the clinical equivalence of tetracyclines and the newer
macrolides in the small number of patients assessed is
noteworthy.
In our study, the patients treated with clarithromycin defer-
vesced more rapidly than did those treated with chloramphen-
icol. It is the largest randomized clinical study yet performed
to assess the newer macrolides as treatment for rickettsial in-
fections in children. Clarithromycin could constitute an ac-
ceptable therapeutic alternative to chloramphenicol and to tet-
racyclines for children aged !8 years who have MSF.
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